Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.73 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960173 | 0.84 | FEN1 (1.00) | FEN1GRM4ADORA2BEGFRSRC | |
| SCHEMBL18687483 | 0.84 | FEN1 (1.00) | FEN1GRM4ADORA2BEGFRSRC | |
| SCHEMBL22017688 | 0.83 | FEN1 (0.65) | FEN1GRM4ALDH1A1ADORA2BEGFR | |
| SCHEMBL22016238 | 0.82 | FEN1 (0.63) | FEN1GRM4KDM4ERXFP1ALDH1A1 | |
| SCHEMBL1609990 | 0.78 | FEN1 (0.56) | FEN1GRM4KDM4EALDH1A1HTT | |
| SCHEMBL3515107 | 0.77 | FEN1 (0.53) | FEN1KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21676725 | 0.77 | FEN1 (0.57) | FEN1GRM4KDM4EALDH1A1HTT | |
| SCHEMBL29376466 | 0.76 | KDM4E (0.59) | FEN1KDM4ERXFP1ALDH1A1HTT | |
| SCHEMBL3197634 | 0.75 | FEN1 (0.55) | FEN1GRM4KDM4EHTTSMN1; SMN2 | |
| SCHEMBL11604423 | 0.75 | FEN1 (0.55) | FEN1GRM4KDM4EALDH1A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184313-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| WO-2016184312-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2086975-B1 | 7,8-DIHYDRO-1,6-NAPHTHYRIDIN-5(6H)-ONES AND RELATED BICYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-0556225-A1 | SUBSTITUTED PYRIDO 2,3-d]PYRIMIDIN-2,4(1H,3H)-DIONES | BASF Aktiengesellschaft (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0243311-B1 | Pyrido[2,3-d]pyrimidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992008719-A1 | SUBSTITUTED PYRIDO[2,3-d]PYRIMIDIN-2,4(1H,3H)-DIONES | BASF AKTIENGESELLSCHAFT (DE) | 1992-05-29 | — | — | WO | disclosed |
| US-4859672-A | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone | RORER PHARMACEUTICAL CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4808587-A | ANTIALLEGENS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1989-02-28 | — | — | US | disclosed |
| EP-0243311-A2 | Pyrido[2,3-d]pyrimidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | FEN1 206/4885GRM4 3693/4885KDM4E 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.